Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

FOXA1 is a key determinant of estrogen receptor function and endocrine response.

Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS.

Nat Genet. 2011 Jan;43(1):27-33. doi: 10.1038/ng.730. Epub 2010 Dec 12.

2.

Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.

Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS, Brown M.

Genes Dev. 2010 Oct 1;24(19):2219-27. doi: 10.1101/gad.1944810.

3.

An oestrogen-receptor-alpha-bound human chromatin interactome.

Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, Ho A, Mei PH, Chew EG, Huang PY, Welboren WJ, Han Y, Ooi HS, Ariyaratne PN, Vega VB, Luo Y, Tan PY, Choy PY, Wansa KD, Zhao B, Lim KS, Leow SC, Yow JS, Joseph R, Li H, Desai KV, Thomsen JS, Lee YK, Karuturi RK, Herve T, Bourque G, Stunnenberg HG, Ruan X, Cacheux-Rataboul V, Sung WK, Liu ET, Wei CL, Cheung E, Ruan Y.

Nature. 2009 Nov 5;462(7269):58-64. doi: 10.1038/nature08497.

4.

Fast and accurate short read alignment with Burrows-Wheeler transform.

Li H, Durbin R.

Bioinformatics. 2009 Jul 15;25(14):1754-60. doi: 10.1093/bioinformatics/btp324. Epub 2009 May 18.

5.

ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands.

Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, Stunnenberg HG.

EMBO J. 2009 May 20;28(10):1418-28. doi: 10.1038/emboj.2009.88. Epub 2009 Apr 4.

6.

ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions.

Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT.

Methods. 2009 Jul;48(3):240-8. doi: 10.1016/j.ymeth.2009.03.001. Epub 2009 Mar 9.

7.

Model-based analysis of ChIP-Seq (MACS).

Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, Liu XS.

Genome Biol. 2008;9(9):R137. doi: 10.1186/gb-2008-9-9-r137. Epub 2008 Sep 17.

8.

FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M.

Cell. 2008 Mar 21;132(6):958-70. doi: 10.1016/j.cell.2008.01.018.

9.

Whole-genome cartography of estrogen receptor alpha binding sites.

Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, Yeo A, George J, Kuznetsov VA, Lee YK, Charn TH, Palanisamy N, Miller LD, Cheung E, Katzenellenbogen BS, Ruan Y, Bourque G, Wei CL, Liu ET.

PLoS Genet. 2007 Jun;3(6):e87. Epub 2007 Apr 17.

10.

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.

Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C.

J Clin Oncol. 2007 Apr 1;25(10):1239-46. Erratum in: J Clin Oncol. 2007 Aug 20;25(24):3790.

PMID:
17401012
11.

Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation.

Nagashima T, Shimodaira H, Ide K, Nakakuki T, Tani Y, Takahashi K, Yumoto N, Hatakeyama M.

J Biol Chem. 2007 Feb 9;282(6):4045-56. Epub 2006 Dec 1. Erratum in: J Biol Chem. 2014 Jul 25;289(30):20491.

12.

Genome-wide analysis of estrogen receptor binding sites.

Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M.

Nat Genet. 2006 Nov;38(11):1289-97. Epub 2006 Oct 1.

PMID:
17013392
13.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

PMID:
16145046
14.

Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.

Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M.

Cell. 2005 Jul 15;122(1):33-43.

15.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Lancet. 2005 May 14-20;365(9472):1687-717.

PMID:
15894097
16.

Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor.

Kun Y, How LC, Hoon TP, Bajic VB, Lam TS, Aggarwal A, Sze HG, Bok WS, Yin WC, Tan P.

Hum Mol Genet. 2003 Dec 15;12(24):3245-58. Epub 2003 Oct 21.

PMID:
14570715
17.

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI.

Endocrinology. 2003 Mar;144(3):1032-44.

PMID:
12586780
18.

Isolation of pure populations of epithelial and myoepithelial cells from the normal human mammary gland using immunomagnetic separation with Dynabeads.

Gomm JJ, Browne PJ, Coope RC, Liu QY, Buluwela L, Coombes RC.

Anal Biochem. 1995 Mar 20;226(1):91-9.

PMID:
7785785

Supplemental Content

Support Center